Do glucagon-like peptide‑1 receptor agonists treat binge‑eating disorder?

GLP-1 Receptor Agonists Show Promise for Binge Eating Disorder But Lack FDA Approval for This Indication

GLP-1 receptor agonists (GLP-1 RAs) appear to reduce binge eating behaviors with moderate effectiveness, but they are not FDA-approved for binge eating disorder (BED) and should be considered investigational for this specific indication. The evidence suggests potential benefit, particularly in patients with comorbid obesity, but significant limitations in study quality and concerns about relapse after discontinuation warrant caution 1, 2.

Current Evidence for Efficacy

The most recent and comprehensive systematic review and meta-analysis (2026) demonstrates that GLP-1 RAs produce moderate reductions in binge eating severity (standardized mean difference = -0.23), with even larger effects observed specifically in trials enrolling participants with diagnosed BED 1. These medications also reduce:

• Loss of control eating (mean difference = -18.38 points)
• Eating disinhibition (effect size = -0.54)
• Emotional eating (effect size = -0.30)

A parallel 2026 systematic review confirms consistent reductions in binge eating behaviors across multiple GLP-1 RAs including liraglutide, semaglutide, and dulaglutide, with improvements in Binge Eating Scale scores and binge frequency 2.

Critical Limitations and Concerns

All available studies were rated as having high risk of bias or some concerns, with substantial heterogeneity in methods and outcomes 1. The evidence base suffers from:

• Small sample sizes (typically <75 participants per study) 2
• Short follow-up durations
• Heterogeneous outcome measures
• Very low overall certainty of evidence 3

The Relapse Problem

A major concern is the high rate of relapse after GLP-1 RA discontinuation. In obesity trials, patients regained 11.6% of lost weight within 52 weeks after stopping semaglutide 4. For BED specifically, one study reported relapse of binge eating symptoms after treatment discontinuation 3. This suggests these medications may need to be used indefinitely, raising questions about long-term sustainability and cost.

Potential Risks in Eating Disorder Populations

While GLP-1 RAs reduce binge eating, they simultaneously increase cognitive/dietary restraint (effect size = 0.31) 1. Whether this represents adaptive self-regulation or pathological restriction remains unclear. More concerning:

• Case reports document extreme appetite suppression and pathological dietary restriction requiring discontinuation 5
• Psychiatric adverse effects including anxiety and depression have been observed 5
• The potent appetite suppression could theoretically exacerbate restrictive eating patterns in vulnerable individuals 6, 5

Clinical Algorithm for Decision-Making

For patients with BED and comorbid obesity (BMI ≥30) or overweight with complications (BMI ≥27):

1. First-line: Cognitive behavioral therapy (CBT) or guided self-help interventions
2. Second-line: Consider GLP-1 RA as adjunctive therapy if:
   • Inadequate response to psychological treatment
   • Significant metabolic complications requiring weight loss
   • Patient has comorbid type 2 diabetes (dual benefit for glycemic control) 3

Screen for contraindications before initiating:

• Active restrictive eating disorder or history of anorexia nervosa
• Severe depression or suicidal ideation (use PHQ-9)
• Body image disturbance suggesting high risk for pathological restriction

If prescribing GLP-1 RA for BED:

• Start with semaglutide (stronger evidence than liraglutide) 4
• Maintain concurrent psychological/behavioral support 7
• Monitor for psychiatric adverse effects monthly
• Use validated measures (Binge Eating Scale) to track response
• Counsel patients that lifelong treatment may be necessary to prevent relapse 4
• Plan for relapse prevention strategies including emotion regulation and maintenance-focused behavioral interventions 7

Special Population: BED with Type 2 Diabetes

In patients with both BED and type 2 diabetes, GLP-1 RAs offer dual benefits for binge eating reduction and glycemic control (HbA1c improvement) 3. However, the evidence remains very low certainty, and relapse after discontinuation has been documented in this population as well 3.

Bottom Line

GLP-1 RAs are not a standalone treatment for BED and should only be considered as part of integrated care with psychological interventions. The moderate efficacy must be weighed against high relapse rates, need for indefinite treatment, cost considerations, and potential psychiatric risks. Until larger, adequately powered trials with longer follow-up are completed, these medications remain investigational for BED specifically 1, 2, 3.